Why the study?
Can a low-density DNA microarray reliably detect known mutations associated with familial hypertrophic cardiomyopathy?
Population
DNA samples with 12 different heterozygous mutations associated with familial hypertrophic cardiomyopathy
Design
Preclinical
Authors
Loading...
Supports preclinical feasibility for HCM mutation arrays; leaves open clinical translation and validation in patients.
Can a low-density DNA microarray reliably detect known mutations associated with familial hypertrophic cardiomyopathy?
A low-density DNA microarray is a feasible, robust, and potentially automatable tool for pre-screening patients for known hypertrophic cardiomyopathy mutations.
Waldmüller et al. (2002) studied this question.